Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04327791 · ClinicalTrials.gov registry record · Phase 2

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

A Phase 2 study, sponsored by Bassett Healthcare.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target

NCT04327791 is a Phase 2 study that has completed, run by Bassett Healthcare. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04327791, a Phase 2 study, has completed, sponsored by Bassett Healthcare.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).

Interventions

  • DRUG Placebos
  • DRUG Baloxavir

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2020-04-03
Est. Completion 2024-10-01
Phase Phase 2

Sponsor

Bassett Healthcare

16 total trials

What the Registry Record Tells You About NCT04327791

The ClinicalTrials.gov registry entry for NCT04327791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bassett Healthcare, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.

NCT04327791 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04327791 about?

NCT04327791 is a clinical study titled "COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)". This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (os...

What is the current status of trial NCT04327791?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-04-03. Estimated completion is 2024-10-01.

What interventions are being tested in trial NCT04327791?

The interventions under investigation include: Placebos (DRUG), Baloxavir (DRUG).

Who is sponsoring clinical trial NCT04327791?

This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.